TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Disease-related QOL (Quality of Life) : EuroQol-5 Dimensions Time Trade-off (EQ-5D TTO)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in metabolic cost of transport
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Any Non-serious Adverse Event (Non-SAE), Serious AE (SAE), Dose Limiting Toxicities (DLT), Dose Reductions or Delays and Withdrawals Due to Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Change From Baseline in Platelets, Neutrophils, Monocytes, Lymphocytes, Leucocyte, Eosinophils and Basophils at Indicated Time-points
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Percentage of Participants With Investigator-assessed Best Response Assessed by Objective Response Rate (ORR)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Contraception Utilization
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Occurrence of a complication
Endpoint domain: Adverse events/effects
Primary endpoint: Presence/absence of a peristomal hernia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Acid base balance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hospital-wide incidence of ARDS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Adherence to evidence-based treatment recommendations
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants Who Experience Treatment Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Simpson Diversity Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patients without evidence of disease progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of Serious Adverse Events in subjects
Endpoint domain: Adverse events/effects
Primary endpoint: Binding antibody responses against EBOV GP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Serious Adverse Events in infants
Endpoint domain: Adverse events/effects
Primary endpoint: Change in IIEF/SHIM score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Size of the acid pocket
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Location of the acid pocket
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Saturation time (s) with toe pressure (mm hg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Amplitude (UA) with toe pressure (mm hg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Slope with toe pressure (mm hg)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Circulatory outcomes
Primary endpoint: Vascularization percentage of the PWS
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Maximum Plasma concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Maximum Urine concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 6-minute-walk Distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiological Success Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Geometric mean PC20 methacholine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Tolerance rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Unscheduled Medical Departures (UMD)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Delayed hypersensitivity reaction prevention
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity/specificity of breast interpretation algorithm
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: vWF concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of peak VO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in physical functioning scale (PFS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in lesion status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient esthetic self perception
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Effects on clinical parameter: sensitivity to percussion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incremental area under the curve for plasma insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Acute Kidney Injury (AKI) documentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Characterization of breath odor during fasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characterization of breath odor during non-fasting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative and quantitative toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Change in LVEF (left ventricular ejection fraction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Area under the serum glucose concentration profile during 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Oswestry Low Back Pain Disability Questionnaire (ODI) Improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Wong Baker Pain Faces Scale mean score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Fear Scale mean score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: treatment failure - need for D&C
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Urinary tract infection diagnosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Nicotine AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: severity of fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: facial emotion recognition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occlusion of the IA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mortality at 30 days after treatment
Endpoint domain: Mortality/survival
Primary endpoint: Change in weight and body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in bone mineral density and bone mineral content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Smoking quit rate at 6-month
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in TMJ pain at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Maximal interincisal opening at 24 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cytomegalovirus (CMV) Reactivation
Endpoint domain: Adverse events/effects
Primary endpoint: AUC (the area under the curve)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax (peak concentration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Imaging outcomes (occlusion results)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Response Rate (CR + CRi + LFS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Receipt of MMR1
Endpoint domain: Adverse events/effects
Primary endpoint: one-year death occurrence
Endpoint domain: Mortality/survival
Primary endpoint: heart failure occurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: cardiovascular hospitalization occurrence
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Maximum cervical spine motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of patients with delivery during workday hours
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Platelet count/spleen diameter ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Child BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Child BMI percent of the 95th percentile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Relative bioavailability of ABT-333 tablet formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Single dose safety and tolerability of ABT-333 tablet formulation
Endpoint domain: Adverse events/effects
Primary endpoint: Single dose pharmacokinetics of ABT-333 tablet formulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in 24 Hour Urine Calcium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area under curve (AUC) of blood alcohol level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Summed Pain Intensity Difference (SPID) on Day 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Protocol-defined Pulmonary Exacerbations Treated
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Child percent body fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduced underarm sweating
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Disability measured by Roland Morris Disability Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Disability measured by Oswestry Disability Index
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Acceptability of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of the intervention
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Scar Quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Accuracy of blood hemoglobin measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Disabilities of the Arm, Shoulder, and Hand (DASH)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Average number of urinations per patient per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Length and Width of Surgical Incision Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Standardized uptake value of 99mTc-HPArk2 in breast tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Responder Outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Orthopaedic Foot and Ankle Society Ankle-Hindfoot Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Victorian Institute of Sport Assessment-Achilles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tegner knee motion score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Densitometry change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscular strength (peak of torque) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional capacity (timed up and go test) change from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of oxaliplatin and 5-FU
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residency time of GRDF furosemide in the gastrointestinal tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants Who Developed Distant Brain Failure
Endpoint domain: Mortality/survival
Primary endpoint: Microfilaria prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Weekly Spontaneous Bowel Movements (SBMs) Per Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean Weekly Bowel Movements (BMs) Per Month
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants That Drop Out
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Pain score during laminaria insertion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Susceptibility to e-cigarette use
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of life
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brief Psychiatric Rating Scale (BPRS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative bladder spasm
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and type of SAEs
Endpoint domain: Adverse events/effects
Primary endpoint: Hematological reconstitution
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reconstitution of cell mediated and humoral immunity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in cardiorespiratory function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Boston Grade of Activity in Lichen Planopilaris
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Heart Rate Variability (SDNN)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Heart Rate Variability (Low Frequency HRV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Cycles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acoustic readings of the abdominal cavity and swallowing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Test-retest reliability of EndoPAT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Bronchial brushings and bronchial alveolar lavage fluid collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mood changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: maximum tolerated dose (MTD) of sunitinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term complication free survival
Endpoint domain: Mortality/survival
Primary endpoint: Pharmacokinetics of aramchol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: venous lactate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of patients receiving liver function tests
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of Participants Able to Hyperextend the Knee After Surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Number of Margins With False Positive Device Readings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EEG mu rhythm suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of 2-fold increase of anti-pneumococcal antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Feasibility of obtaining force data
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose (MTD) of sorafenib tosylate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensor quality validation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Staging of breast cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Changes in self-regulation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Best-Corrected Visual Acuity of Amblyopic Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Best-Corrected Visual Acuity of Fellow Eye
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Significant recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Improvement in 3 Month-Post Treatment QOL Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Improvement in 6 Month-Post Treatment QOL Scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Total recovery of tritium, [3H]-liraglutide and metabolites
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Walked distance in 6MWT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Foot pressure assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Any PAE Within 7 Days
Endpoint domain: Adverse events/effects
Primary endpoint: Freedom From Documented Atrial Fibrillation (AF), Atrial Tachycardia (AT), or Atrial Flutter (AFL) Episodes Through 15-month Follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Type and severity of side effects
Endpoint domain: Adverse events/effects
Primary endpoint: Clinical remission after 12 weeks EEN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mucosal healing after EEN
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Angular Tremor Amplitude of the Wrist
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Incidence of Bacterial Ventriculitis, Meningitis
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of Symptomatic Bleeding Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Accelerometer Measured Moderate to Vigorous Physical Activity (MVPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of a Device Oriented Composite Endpoint (DOCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Concentration and Number of CD8+ Cells Infiltrating Tumor
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of suspected OHCA cases with AED-drone dispatched and mission completed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mass spectrometric exhaled breath pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum lactate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: creatine kinase concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: intraoperative complications requiring conversion
Endpoint domain: Adverse events/effects
Primary endpoint: Acceptability of HealthyDads.ca
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change from baseline in post-bronchodilator FEV1 (percent predicted)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of patients with at least one pulmonary exacerbation
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of onycholysis Gr 2 or more
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Activated GZMB+ CD8+ T-cell Density Intratumorally
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Contraceptive method continuation
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Contraceptive method satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Cognitive inhibitory performance on Stroop task (reaction time)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Intertemporal choice task (discount parameter)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Opioid and cocaine use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social and psychological functioning
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: AIDS risk behavior
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major post extubation laryngeal edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reported genitourinary symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes